Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML

Noah I. Hornick, Jianya Huan, Ben Doron, Natalya A. Goloviznina, Jodi Lapidus, Bill H. Chang, Peter Kurre

Research output: Contribution to journalArticle

87 Scopus citations

Abstract

Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with advanced disease and poorly reflect MRD during early relapse. Here, we investigate exosomes as a minimally invasive platform for a microRNA (miRNA) biomarker. We identify a set of miRNA enriched in AML exosomes and track levels of circulating exosome miRNA that distinguish leukemic xenografts from both non-engrafted and human CD34+ controls. We develop biostatistical models that reveal circulating exosomal miRNA at low marrow tumor burden and before circulating blasts can be detected. Remarkably, both leukemic blasts and marrow stroma contribute to serum exosome miRNA. We propose development of serum exosome miRNA as a platform for a novel, sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.

Original languageEnglish (US)
Article number11295
JournalScientific Reports
Volume5
DOIs
StatePublished - Jun 12 2015

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML'. Together they form a unique fingerprint.

  • Cite this